Tracy McGregor, MD, Senior Director of Clinical Research at Alnylam Pharmaceuticals, discusses medical management options for primary hyperoxaluria type 1 (PH1).

PH1 is a rare genetic disease in which excessive oxalate production leads to painful and recurrent kidney stones. These recurrent stones increase the chance of hematuria, urinary tract infections, and end stage renal disease (ESRD). 

As Dr. McGregor explains, hyperhydration is a common course of action for PH1 patients in order to flush out oxalate buildup. Crystallization inhibitors are also commonly prescribed.  Some patients also take vitamin B6, though data suggests that noticeable improvement in urinary oxalate levels occurs in only a small minority of PH1 patients. In November 2020, the U.S. Food and Drug Administration (FDA) approved lumasiran to treat PH1.

To learn more about PH1 and other rare kidney diseases, visit